INSIGHT 2 : a Phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance
Source
Future oncology - ISSN 1479-6694- () p.
Neoadjuvant systemic therapy for pleural mesothelioma patients : a systematic review
Source
Translational lung cancer research - ISSN 2218-6751-14:10 (2025) p. 1-12
Methylation biomarkers can distinguish pleural mesothelioma from healthy pleura and other pleural pathologies
Source
Molecular Oncology - ISSN 1574-7891- (2025) p.
Radical surgery in pleural mesothelioma : Houston, we have a problem
Source
Journal of thoracic oncology - ISSN 1556-0864-20:5 (2025) p. e59-e60
Genome-wide DNA methylation analysis reveals a unique methylation pattern for pleural mesothelioma compared to healthy pleura and other lung diseases
Source
Clinical epigenetics - ISSN 1868-7075-16:1 (2024) p. 1-17